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Objective: To investigate the effectiveness of GnRH antagonist multiple-dose protocol (MDP) with oral contraceptive pill (OCP) pretreatment 
in poor responders undergoing IVF/ICSI, compared with GnRH antagonist MDP without OCP pretreatment and GnRH agonist low-dose long 
protocol (LP). 
Methods: A total of 120 poor responders were randomized into three groups according to controlled ovarian stimulation (COS) options; GnRH 
antagonist MDP after OCP pretreatment (group 1), GnRH antagonist MDP without OCP pretreatment (group 2) or GnRH agonist luteal low-dose 
LP without OCP pretreatment (group 3). Patients allocated in group 1 were pretreated with OCP for 21days in the cycle preceding COS, and ovar-
ian stimulation using recombinant human FSH (rhFSH) was started 5 days after discontinuation of OCP. 
Results: There were no differences in patients’ characteristics among three groups. Total dose and days of rhFSH used for COS were significantly 
higher in group 3 than in group 1 or 2. The numbers of mature oocytes, fertilized oocytes and grade I, II embryos were significantly lower in group 
2 than in group 1 or 3. There were no significant differences in the clinical pregnancy rate and implantation rate among three groups.
Conclusion: GnRH antagonist MDP with OCP pretreatment is at least as effective as GnRH agonist low-dose LP in poor responders and can be-
nefit the poor responders by reducing the amount and duration of FSH required for follicular maturation. 
Keywords: Gonadotropin-releasing hormone; Antagonist; Agonist; Oral Contraceptives; Poor Responders; In vitro fertilization; Intracytoplasmic 
sperm injection; Human
Introduction 
The management for poor responders with diminished ovarian re-
serve is still a challenge, although many studies have been performed 
to seek for a method of efficient ovarian stimulation for infertile wom-
en with reduced ovarian reserve. There have been many studies as-
sessing various controlled ovarian stimulation (COS) regimens to im-
prove the outcome of poor responders undergoing IVF, no particular 
protocol was demonstrated to be best suited for all such patients [1]. 
GnRH agonist long protocol (LP) has been a standard COS method 
since it was introduced in assisted reproduction in the late 1980’s to 
prevent premature LH surge and luteinization [2], and GnRH agonist 
low-dose regimens was advocated as one of important protocols for 
poor responders in terms of improvement in COS response and re-
duced duration and dose of gonadotropin stimulation [3,4]. More re-
cently, GnRH antagonists have been administered to poor respond-
ers during COS with inconsistent results [5-9]. Although a limited num-
ber of randomized controlled trials compare the efficacy of GnRH an-
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tagonist protocol and the agonist long protocol for COS in poor re-
sponders undergoing IVF, a meta-analysis by Griesinger et al. [10] 
demonstrated that GnRH antagonist protocol results in significantly 
more cumulus oocyte complexes (COCs) and similar clinical outcome. 
COS using GnRH antagonists is also likely to become one of the treat-
ment options for poor responders. 
After the introduction of GnRH antagonists in COS, oral contracep-
tive pill (OCP) has been used for cycle scheduling purpose. OCP is ef-
fective in allowing prediction of timing events in an IVF cycle regard-
ing scheduling and is frequently used before IVF and may influence 
IVF outcome [11,12]. In a randomized controlled trial by Kolibianakis 
et al. [13] and a meta-analysis by Griesinger et al. [14], a significant 
difference in ongoing pregnancy rates between patients who receiv-
ed OCP pretreatment and those who did not was not found. Howev-
er, subjects for these studies were not poor responders and the avail-
able randomized studies on OCP pretreatment in poor responders 
undergoing IVF have not been reported. It is thought that OCP pre-
treatment in GnRH antagonist cycles can result in different ovarian 
response to COS and IVF results in poor responders, compared with 
normal responders. 
The present study was performed to investigate the effectiveness 
of GnRH antagonist multiple-dose protocol (MDP) with OCP pretreat-
ment in poor responders undergoing IVF/ICSI, compared with GnRH 
antagonist MDP without OCP pretreatment and GnRH agonist low-
dose LP.
Methods
1. Patient population
A total of 120 poor responders, aged 28-41 years, who were defin-
ed as patients with repeated day 3 levels of FSH>8.5 mIU/mL [15], 
and/or antral follicle count (AFC)≤5 [16,17], were recruited from a 
university-based infertility clinic at the Asan Medical Center, Seoul, 
Korea. The Institutional Review Board of our center approved the study 
and all patients provided written informed consent. Patients were 
randomized on the basis of a computer-generated list to three groups 
according to COS options; GnRH antagonist MDP after OCP pretreat-
ment (group 1), GnRH antagonist MDP without OCP pretreatment 
(group 2) or GnRH agonist luteal low-dose long protocol without OCP 
pretreatment (group 3). The sequence of allocation to the three groups 
was provided to the investigating physicians and randomization was 
performed as planned according to the randomization list order. All 
three groups consisted of 40 cycles initiated corresponding to 40 pa-
tients, respectively. A probability by power calculation for sample size 
determination was 81%.
All patients were in good health with normal hepatic, and renal func-
tions with a body mass index of between 19 and 30 kg/m
2. None of 
subjects had ever taken any infertility medications (clomiphene and/
or gonadotropins) within the preceding three months. Patients with 
polycystic ovary syndrome according to Rotterdam definition were 
excluded from this study. Hormonal profiles (serum levels of basal 
FSH, LH, E2, prolactin, testosterone and antimϋllerian hormone) and 
the number of basal antral follicle in ultrasonogram were measured 
on the 2nd or 3rd day of menstruation in all patients. 
2. Ovarian stimulation protocols
All patients allocated in group 1 were pretreated identically with 
Minivlar (ethinyl estradiol 0.03 mg and levonorgestrel 0.15 mg; Scher-
ing AG, Berlin, Germany) for 21 days in the cycle preceding COS. Five 
days after OCP discontinuation for group 1 and on cycle day 3 for 
group 2, ovarian stimulation was commenced using recombinant 
human FSH (rhFSH, Gonal-F; Merck Serono SA, Geneva, Switzerland) 
of 225 IU/day after establishing ovarian and uterine quiescence using 
vaginal ultrasound. The rhFSH dose was adjusted according to ovari-
an response, every 3-4 days. GnRH antagonist (Cetrotide 0.25 mg; 
Merck Serono SA) was started when the leading follicle reached 14 
mm in average diameter, and was continued daily until the day of 
hCG administration. A recombinant hCG (rhCG, Ovidrel; Merck Sero-
no SA) of 250 μg was injected to induce follicular maturation when 
one or more follicles reached a mean diameter of ≥18 mm. Oocyte 
retrieval was performed 35 to 36 hours after hCG injection and one 
to four embryos were transferred into the uterus on the third day af-
ter oocyte retrieval. Vaginal progesterone gel (Crinone 8%, 90 mg, 
Merck Serono SA) once daily was administrated from the day of oo-
cyte retrieval, for luteal support. In group 3, the daily injection of GnRH 
agonist (Decapeptyl 0.1 mg; Ferring, Malmö, Sweden) was initiated 
from the midluteal phase and continued until menses followed by a 
dose reduction to 0.05 mg daily. GnRH agonist 0.05 mg daily was 
continued up to day of hCG administration. Ovarian stimulation us-
ing rhFSH, oocyte retrieval and luteal support were performed in the 
same manner with GnRH antagonist MDP.
The serum level of β-hCG was measured 11 days after embryo trans-
fer (ET). Measurement of β-hCG was performed by radioimmunoas-
say using a hCG MAIAclone kit (Serono Diagnostics, Woking, UK); in-
terassay and intraassay variances were less than 10% and 5%, respec-
tively. 
3. Outcome measures 
Primary efficacy endpoint was the number of mature oocytes re-
trieved. Secondary efficacy variables included total amount and days 
of rhFSH administered, the numbers of fertilized oocytes and grade I, 
II embryos, implantation rate, clinical pregnancy rate per cycle, and 
live birth rate per cycle.
Clinical pregnancy was defined as the presence of a gestational sac   http://dx.doi.org/10.5653/cerm.2011.38.4.228
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by ultrasonography 5 weeks after oocyte retrieval, while miscarriage 
rate per clinical pregnancy was defined as the proportion of patients 
who failed to continue development before 20 weeks of gestation in 
all clinical pregnancies. Live birth was defined as the delivery of a fe-
tus with signs of life after twenty four completed weeks of gestation-
al age.
4. Statistical analysis
The mean value was expressed as the mean±SD. Analysis of vari-
ance was used to compare the mean values among three groups. 
Chi-square test and Fisher’s exact test were used for the comparisons 
of fraction. Statistical significance was defined as p<0.05. All analy-
ses were performed using the SPSS statistical package for Windows, 
ver. 12.0 (SPSS Inc, Chicago, IL, USA). 
Results
There were no differences in the age of patients, duration of infertil-
ity, body mass index, the proportion of nullipara, AFC and basal en-
docrine profile among three groups (Table 1). 
In group 1 and 3, no patient was lost to follow-up or withdrawn 
from the study and there were no cancellation of cycle by premature 
LH surge or any other reasons. In group 2, 1 out of 40 cycles initiated 
(2.5%) was cancelled before ET, because no oocytes were obtained 
despite a follicular aspiration for oocyte retrieval. However, there was 
no significant difference in cycle cancellation rate among three groups 
(Table 2). 
Total doses (2,925.0±423.9 IU vs. 2,905.0±421.8 IU vs. 3,273.6± 
438.3 IU) and days (9.9±1.3 days vs. 9.8±1.3 days vs. 11.3±1.5 days) 
of rhFSH required for COS were significantly higher in group 3 than in 
group 1 or 2 (p<0.001, p<0.001) (Table 2). The number of follicles ≥ 
14 mm and endometrial thickness on hCG day, number of oocytes 
retrieved were similar among three groups, but the number of ma-
ture oocytes (4.0±1.6 vs. 2.8±1.2 vs. 3.8±1.6), fertilized oocytes (3.9 
±1.6 vs. 2.8±1.1 vs. 3.8±1.6) and grade I, II embryos (2.2±1.1 vs. 1.3 
±0.9 vs. 2.1±1.0) were significantly lower in group 2 than in group 1 
or 3 (p=0.001, p=0.002, p<0.001, respectively) (Table 2). However, 
significant differences were not found among three groups regard-
ing clinical pregnancy rate per cycle initiated, implantation rate and 
live birth rate per cycle initiated (Table 2).
Discussion
The present study evaluated the effectiveness of GnRH antagonist 
MDP with or without OCP pretreatment, compared with GnRH ago-
nist low-dose LP that have been popularly used since the 1990’s in 
poor responders undergoing IVF/ICSI. Total dose and duration of rhFSH 
used for COS were significantly higher in GnRH agonist low-dose LP 
group than in GnRH antagonist MDP groups, which suggests the ad-
vantage of GnRH antagonist protocol. It is well known advantage of 
GnRH antagonist protocols compared with GnRH agonist LP, and 
Howles et al. [18] reported that the GnRH antagonists offer compara-
ble therapeutic efficacy to agonists and have a number of potential 
advantages over agonists for use in COS protocols, such as avoiding 
the initial “flare-up” of LH, shortening the overall treatment period 
and reducing the risk of OHSS and menopausal side effects in wom-
en of advanced maternal age. In group 1, the numbers of mature oo-
cytes, fertilized oocytes and grade I, II embryos were comparable to 
those in group 3, whereas these were significantly lower in group 2. 
This implicates OCP pretreatment in GnRH antagonist MDP is effec-
tive in improving the ovarian response to COS and IVF outcome with 
similar level to GnRH agonist low-dose LP. In patients with elevated 
basal serum FSH levels by diminished ovarian reserve, antral follicle 
sizes during the early follicular phase are often markedly heteroge-
neous because FSH-sensitive follicles are early exposed to gradient 
FSH concentrations during the preceding luteal phase. Therefore, in 
poor responders, ovarian stimulation without pituitary suppression 
is likely to induce asynchronous follicular development and a limited 
number of dominant follicles. The COS results of present study may 
result from pituitary suppression prior to ovarian stimulation. Actual-
ly, a study by Fanchin et al. [19] showed that luteal FSH suppression 
by either estradiol or GnRH antagonists administration improves the 
homogeneity of early antral follicles during the early follicular phase, 
thereby improving ovarian response to short GnRH agonist and an-
tagonist protocols. 
Table 1. Patients’ characteristics 
Group 1
(MDP with 
OCP)
Group 2
(MDP with-
out OCP)
Group 3
(GnRH ago-
nist low-
dose LP)
p-value
No. of patients 40 40 40
Age of patients (yr) 36.7±3.1 35.9±2.8 36.4±3.3 NS
a
Duration of infertility (mo)  50.1±20.4  46.8±18.8  51.3±22.5 NS
a
Body mass index (kg/m
2) 22.1±2.4 22.1±2.1 22.3±2.5 NS
a
No. of nullipara   19 (47.5)  21 (52.5)  22 (55.0) NS
b
Antral follicle count  4.6±1.5 4.7±1.6 4.7±1.7 NS
a
Basal serum FSH (IU/L) 8.8±1.2 8.6±1.0 8.8±1.2 NS
a
Basal serum LH (IU/L) 5.0±1.4 5.3±1.2 5.2±1.3 NS
a
Basal serum E2 (pg/mL) 48.3±9.6 46.5±8.6 47.2±9.3 NS
a
Serum PRL (ng/mL) 13.1±2.2 14.1±2.7 13.5±2.3 NS
a
Serum T (ng/mL)  0.3±0.2  0.3±0.2  0.2±0.3 NS
a
Serum AMH (ng/mL)  1.5±0.5  1.6±0.5  1.4±0.6 NS
a
Values are presented as mean±SD or number (%).
MDP, multiple-dose protocol; OCP, oral contraceptive pill; LP, long protocol; 
AMH, antimϋllerian hormone; NS, not significant.
aAnalysis of variance; 
bChi-square test.www.eCERM.org
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In terms of clinical pregnancy rate in our study, GnRH antagonist 
MDP with OCP pretreatment seemed to work better than GnRH an-
tagonist MDP without OCP pretreatment, but the difference was not 
statistically significant. GnRH antagonist MDP with OCP pretreatment 
yielded comparable IVF results and pregnancy outcome to GnRH ag-
onist low-dose LP with fewer dose and days of rhFSH required. 
Assessment of various COS regimens for poor responders is difficult 
because there is no universal definition for poor responder and lack 
of a large number of prospective randomized trials demonstrating 
the advantage of a specific single protocol [20]. However, low-dose 
GnRH agonist protocols, microdose GnRH agonist flare regimens and 
GnRH antagonist protocols are considered as beneficial regimens in 
poor responders [1,20]. Olivennes et al. [4] prospectively analyzed 98 
patients with low-dose GnRH agonist protocol, which leuprolide ace-
tate of 0.5 mg daily was initiated in the mid-luteal phase and then 
decreased to 0.25 mg daily after menses when gonadotropin stimu-
lation was commenced. They reported improvement of COS results 
with reduced duration and doses of gonadotropin stimulation. Sev-
eral studies have recently evaluated GnRH antagonist protocols com-
paring to alternative regimens designed for poor responders. Cop-
perman suggested GnRH antagonist protocol in poor responders 
could reduce the cancellation rate of the cycle and increase the on-
going pregnancy rate, when compared with GnRH agonist micro-
dose flare protocol [21]. Cheung et al. [22] also reported a fixed, mul-
tiple-dose GnRH antagonist protocol could be utilized for poor re-
sponders although they failed to demonstrate an overall improve-
ment in ovarian responsiveness. These recent studies implicate the 
effectiveness of GnRH antagonist use in COS for poor responders. 
The OCP pretreatment in IVF cycles is the simplest method for cycle 
scheduling, and it can be beneficial in improving ovarian responses 
by inhibition of intrinsic gonadotropins before ovarian stimulation. A 
recent meta-analysis demonstrated no significant differences be-
tween patients with and those without OCP pretreatment regarding 
the number of cumulus-oocyte complexes, fertilization rates and on-
going pregnancy rates [14]. However, we showed OCP pretreatment 
in GnRH antagonist cycles can offer advantages in IVF results in poor 
responders. Copperman also reported a higher proportion of patients 
obtained more than eight oocytes, a significantly higher pregnancy 
rate when OCP pretreatment was performed in poor responders [21]. 
It is thought that OCP pretreatment in GnRH antagonist cycles can 
result in different ovarian response to COS and IVF results in poor re-
sponders, compared with normal responders, and OCP pretreatment 
Table 2. Comparison of controlled ovarian stimulation results and IVF/ICSI outcome
Group 1 
(MDP with OCP)
Group 2 
(MDP without OCP)
Group 3 
(GnRH agonist low-dose LP) p-value
No. of cycles initiated 40 40 40
No. of cycles retrieved 40 40 40
No. of ET cycles  40 39 40
No. of cycles cancelled   0 1 (2.5)   0 NS
a
Total dose of rhFSH (IU) 2,925.0±423.9 2,905.0±421.8 3,273.6±438.3 <0.001
b
Days of rhFSH injected 9.9±1.3 9.8±1.3 11.3±1.5 <0.001
b
On the day of hCG injection
No. of follicles≥14 mm  4.8±1.8  4.3±1.3  4.5±1.4 NS
b
EMT (mm) 10.2±1.7 10.4±1.7 10.5±1.9 NS
b
No. of cycle with premature LH surge 0 0 0 NS
a
No. of cycles with ICSI 19 (47.5) 16 (40.0)      18 (45.0) NS
a
No. of oocytes retrieved 4.9±2.0 4.2±1.7 4.8±1.9 NS
b
No. of mature oocytes 4.0±1.6 2.8±1.2 3.8±1.6 0.001
b
No. of fertilized oocytes 3.9±1.6 2.8±1.1  3.8±1.6 0.002
b
No. of grade I, II embryos 2.2±1.1 1.3±0.9 2.1±1.0 <0.001
b
No. of embryos frozen 0.3±0.6 0.1±0.2 0.3±0.5 NS
b
No. of embryos transferred 2.9±0.2  2.8±0.2 2.9±0.3 NS
b
Clinical PR per cycle initiated (%) 37.5 (14/40) 22.5 (9/40) 32.5 (13/40) NS
a
Implantation rate (%)  15.5 (18/116)   9.6 (11/114) 13.7 (16/117) NS
a
Miscarriage rate per clinical pregnancy  (%) 14.3 (2/14) 11.1 (1/9) 15.4 (2/13) NS
a
Live birth rate per cycle initiated (%)  30.0 (12/40) 20.0 (8/40) 27.5 (11/40) NS
a
Twin PR per clinical pregnancy (%) 28.6 (4/14) 20.0 (2/10) 23.1 (3/13) NS
a
Values are presented as mean±SD or number (%).
MDP, multiple-dose protocol; OCP, oral contraceptive pill; LP, long protocol; ET, embryo transfer; EMT, endometrial thickness; PR, pregnancy rate; NS, not signifi-
cant.
aChi-square test or Fisher’s exact test; 
bAnalysis of variance.   http://dx.doi.org/10.5653/cerm.2011.38.4.228
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might be more advantageous in poor responders than in normal re-
sponders. 
The present study demonstrated that GnRH antagonist MDP with 
OCP pretreatment is at least as effective as GnRH agonist low-dose 
LP in poor responders and can be advantageous to poor responders 
because of the shortened time required for follicular maturation and 
the diminished amount of rhFSH required to provide adequate ovari-
an stimulation. Therefore, GnRH antagonist protocol with OCP pre-
treatment might be a useful choice of COS for poor responders. Larg-
er studies with standardized methods will be needed for confirma-
tion of our conclusions.
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